Andrew Lucas, M.S., Pharm.D.
120 Mason Farm Road, 1019 Genetic Medicine Building, CB# 7361, Chapel Hill, NC, 27599
As a trained pharmacist and clinical pharmacologist, Dr. Lucas has been involved in cancer research for over 11 years and translational/clinical studies of complex pharmacologic formulations for over 9 years. He is intrigued by the interconnections between the drug’s pharmacology, pharmacokinetics (PK), and pharmacodynamics (PD), and their impact on efficacy and toxicity, especially when considering these factors for bedside patient care. He has been highly trained to perform the detailed analytical and pharmacology studies required for the translational development of complex agents (e.g. monoclonal antibodies, PEGylated therapeutic proteins, immune-modulating agents) in patients and preclinical models. He also leads the development of new analytical platforms to measure drugs within different cells types as part of in vivo studies and functional platforms of the innate immune system to predict variation in patient outcomes. Through his research, he strives to improve the lives of patients by contributing to our current understanding of drug toxicity, pharmacokinetics, and early detection of a patient’s response; translating exceptional benchtop science into patient survival.